First participant dosed in Ionis’ Phase I-II ASCEND study

Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337 for children with Dravet syndrome. The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome. Dravet syndrome is characterised by early onset, prolonged seizures, developmental delays and a risk of sudden death. Credit: SkazovD / Shutterstock.com. Ionis Pharmaceuticals has dosed the first participant in its Phase I-II ASCEND trial evaluating ION337, an investigational ribonucleic acid (RNA)-targeted therapy, for children with Dravet syndrome. Dravet syndrome is a rare and severe neurological disorder characterised by early onset, prolonged…

Source: Clinical Trials Arena